Mabion S.A. (WSE:MAB)

Market Cap	121.86M -30.8%
Revenue (ttm)	15.76M -77.2%
Net Income	-62.61M
EPS	-3.87
Shares Out	16.16M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38,026
Average Volume	33,102
Open	7.45
Previous Close	7.42
Day's Range	7.45 - 7.74
52-Week Range	6.70 - 10.28
Beta	0.41
RSI	38.32
Earnings Date	Apr 28, 2026

About Mabion

Mabion S.A., a biopharmaceutical company, provides services as a contract development and manufacturing organization in the process development, analytics, and manufacturing of biologic medicines in Poland. It offers drug substance manufacturing, fill and finish, gene to vial end-to-end development, process development, analytics, and banking services. In addition, it offers cell line development, process development, production of a product for preclinical and clinical trials, development and validation of analytical methods, and preparation o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 213
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: MAB

Financial Performance

In 2025, Mabion's revenue was 15.76 million, a decrease of -77.17% compared to the previous year's 69.02 million. Losses were -62.61 million, 888.5% more than in 2024.